Merus Labs International Inc (TSE:MSL) had its price objective raised by investment analysts at Dundee Securities from C$3.50 to C$3.60 in a note issued to investors on Tuesday, StockTargetPrices.com reports. The firm presently has a “buy” rating on the specialty pharmaceutical company’s stock. Dundee Securities’ price target would indicate a potential upside of 60.00% from the company’s current price.

Merus Labs International (TSE:MSL) traded down 6.22% on Tuesday, hitting $2.11. The company had a trading volume of 2,381,889 shares. Merus Labs International has a one year low of $1.47 and a one year high of $3.50. The stock’s 50-day moving average price is $1.93 and its 200 day moving average price is $2.08. The company’s market capitalization is $215.86 million.

In other Merus Labs International news, Director Barry Fishman acquired 100,000 shares of the company’s stock in a transaction dated Thursday, December 10th. The shares were bought at an average cost of C$1.72 per share, with a total value of C$172,270.00.

Several other equities research analysts also recently weighed in on the company. Mackie downgraded Merus Labs International from a “buy” rating to a “hold” rating and cut their price objective for the company from C$2.70 to C$1.90 in a report on Tuesday, December 8th. Canaccord Genuity reaffirmed a “buy” rating and set a C$3.25 target price (down from C$4.00) on shares of Merus Labs International in a report on Thursday, October 8th. Scotiabank set a C$2.80 target price on Merus Labs International and gave the stock an “outperform” rating in a report on Thursday, October 15th. Paradigm Capital cut their target price on Merus Labs International from C$3.85 to C$2.10 and set a “buy” rating on the stock in a report on Wednesday, December 9th. Finally, CIBC initiated coverage on Merus Labs International in a report on Monday, November 30th. They set a “sector outperformer” rating and a C$2.90 target price on the stock. One research analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of C$3.18.

Merus Labs International Inc. (TSE:MSL) is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products in Canada and internationally. It carries out business principally in Canada and Europe. The Company has products in the area of urology/women’s health and anti-infectives. Its products include Factive, Emselex/Enable and Vancocin. Enablex (darifenacin) or Emselex is used in treatment of urinary urgency and incontinence. Vancocin is used in treatment of C. difficile infection (CDI). Factive (Gemifloxacin Mesylate tablets) is the only Food and Drug Administration approved quinolone with five day oral dosing indicated for the treatment of both acute bacterial exacerbation of chronic bronchitis and mild to moderate community-acquired pneumonia.

Stock Target Prices

Frustrated with your broker? Are you tired of paying high fees? Do you feel like you are getting ripped off by your stock broker? It's time for a change. Find out which brokerage is best for your personal trading style at the InvestorPlace Broker Center. Compare brokers at a glance in the InvestorPlace Broker Center (Click Here).

Receive News & Ratings for Merus Labs International Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International Inc and related companies with MarketBeat.com's FREE daily email newsletter.